Quantcast

Industry news that matters to you.  Learn more

Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

Biodesix presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the AACR-NCI-EORTC conference. The study was conducted in collaboration with Dr. Michael Pritchett, from FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, and Dr. Jiaxin Niu, from Banner MD Anderson Cancer Center.

Big Pharma Joins NIH’s Cancer Moonshot for a Biomarker Hunt

Eleven drug companies are joining forces with the U.S. National Institutes of Health’s Cancer Moonshot to expedite the discovery of cancer immunotherapy biomarkers, molecular bar codes that help doctors know how to treat a tumor and gauge how well a person responds to a drug.

ImmunID Signs Master Collaboration Agreement with MSK About the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR

ImmunID, the immune companion diagnostics for precision medicine company, recently announced that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world’s oldest and largest private cancer center. It has ranked as one of the top two hospitals for cancer care in the United States for more than 25 years.

Collaboration Led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy Using ImmunTraCkeR

ImmunID, the immune companion diagnostics for precision medicine company, recently announced it has been awarded Small Business Research Initiative funding1 by Innovate UK, UK’s innovation agency, to advance its ImmunTraCkeR® assay for therapeutic response prediction. The project aims at validating ImmunID’s clinical results with ImmunTraCkeR® through a clinical study on 40 metastatic melanoma patients from the UK, treated with immunotherapy. It also includes a medico-economic study to measure the health economic benefits for the National Health Service (NHS), the UK healthcare system. The National Institute for Health Research Diagnostic Evidence Co-operative Leeds (NIHR DEC Leeds) and the Precision Medicine Catapult are collaborating on the project. The Catapult’s Centres of Excellence in Leeds and Glasgow will provide health-informatic and data-analytic support to mine local and national health records, providing real world NHS data for the economic modelling. Ultimately, ImmunTraCkeR® may be used as an immune companion diagnostic to immune checkpoint agents and help doctors make informed decisions regarding the treatment of melanoma, therefore improving patient benefit whilst saving unnecessary healthcare costs.

OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer

OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company has enrolled the first patient into a pilot biomarker trial of ImmunoPulse™ IL-12 in patients with triple negative breast cancer (TNBC). ImmunoPulse™ IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to enhance tumor immunogenicity, leading to increased tumor infiltrating lymphocytes (TILs) and pro-inflammatory cytokines.